Inclisiran for fast-track lipid-lowering treatment early after an acute coronary syndrome: a pilot study

Background: Elevated low-density lipoprotein cholesterol (LDL-C) after acute coronary syndrome (ACS) significantly increases cardiovascular risk. Timely reduction of LDL-C is crucial, but it takes several weeks to achieve optimal LDL-C levels with standard therapy. Monoclonal antibodies that inhibit...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Alessandro Lupi, Martino Baluci, Simone Persampieri, Iacopo Perversi, Davide Presutti, Alberto Somaschini, Giovanni Vincenzo Gaudio, Luigina Guasti, Marc Ferrini, Alberto Corsini, Roberto De Ponti
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-12-01
coleção:	Atherosclerosis Plus
Assuntos:	Acute coronary syndrome Low-density lipoprotein cholesterol PCSK9 inhibitors Inclisiran Lipid-lowering therapy
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2667089525000264
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!